Movers and SHAKERS
Cocrystal Pharma Inc. (COCP)
Q3 EPS: Pipeline Remains on Track
Cocrystal Pharma Inc is a clinical stage biotechnology company discovering and developing novel antiviral therapeutics that target the replication machinery of influenza viruses, hepatitis C viruses, and noroviruses. The company employs structure-based technologies and Nobel Prize-winning expertise to create first-and best-in-class antiviral drugs. It is developing CC-31244, an investigational, oral, broad-spectrum replication inhibitor called a non-nucleoside inhibitor (NNI). CC-31244 is currently being evaluated in a Phase 2a study for the treatment of hepatitis C as part of a cocktail for ultra-short therapy of 4 to 6 weeks.
Ahu Demir, Ph. D., Biotechnology Research Analyst, Noble Capital Markets, Inc.
Refer to the full report for the price target, fundamental analysis, and rating.
Q3 2020 financial results. In 3Q, Cocrystal's net loss was $2.7 million. In the 9-months of 2020, net loss was $8.1 million. The company ended the quarter with $31.8 million in cash and cash equivalents. Earnings per share (EPS) loss was ($0.05) in the quarter.
Model update. We updated our estimates, according to the reported numbers and reflecting the increase in operating expenses attributed to the additional clinical trial commencement. We now forecast $2.0 million, $2.1 million, and $2.4 million in revenues, $12.8 million, $14.5 million, and $15.8 million operating expenses, and ($0.20), ($0.18), and ($0.11) in EPS for F2020, F2021 and F2021 ...
This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).
*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision.